Drug Discovery & Development: JET Promotes 3Rs of Animal Studies

Dec 04 2012

Drug Discovery & Development

Recent technological advances have dramatically broadened the scope of safety pharmacology studies as originally envisioned in the International Conference on Harmonization (ICH) S7A and S7B guidances. Recent revisions to the ICH S6(R1) guidance state that safety pharmacology “may be investigated in separate studies or incorporated in the design of toxicity studies” for biotechnology-derived products. In the context of these guidelines, jacketed telemetry has emerged as a technology capable of integrating high-quality cardiovascular safety studies with repeat-dose toxicology studies, thus accelerating drug development timelines. Jacketed telemetry is also closely aligned with the “3Rs” of animal use.

Click here to learn more in an article by Robert A. Kaiser, Senior Research Scientist and Henry H. Holzgrefe, Senior Scientific Advisor, Charles River Preclinical Services.